Johnson & Johnson (NYSE:JNJ) Shares Sold by Sargent Investment Group LLC

Sargent Investment Group LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 21,441 shares of the company’s stock after selling 338 shares during the period. Sargent Investment Group LLC’s holdings in Johnson & Johnson were worth $3,475,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. Omnia Family Wealth LLC grew its stake in Johnson & Johnson by 22.3% during the 3rd quarter. Omnia Family Wealth LLC now owns 3,033 shares of the company’s stock valued at $492,000 after acquiring an additional 553 shares in the last quarter. Intelligence Driven Advisers LLC purchased a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $243,000. Tokio Marine Asset Management Co. Ltd. lifted its holdings in Johnson & Johnson by 5.4% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 66,313 shares of the company’s stock valued at $10,747,000 after acquiring an additional 3,392 shares during the last quarter. Metis Global Partners LLC raised its position in Johnson & Johnson by 3.2% in the third quarter. Metis Global Partners LLC now owns 138,758 shares of the company’s stock valued at $22,487,000 after purchasing an additional 4,283 shares during the period. Finally, Curi RMB Capital LLC increased its position in shares of Johnson & Johnson by 2.2% during the 3rd quarter. Curi RMB Capital LLC now owns 104,083 shares of the company’s stock worth $16,868,000 after purchasing an additional 2,239 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on JNJ shares. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Royal Bank of Canada upped their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. TD Securities cut their price objective on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Finally, Wells Fargo & Company boosted their target price on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.00.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 22.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.9 %

JNJ stock opened at $151.86 on Friday. The company has a market cap of $365.62 billion, a price-to-earnings ratio of 21.98, a price-to-earnings-growth ratio of 2.72 and a beta of 0.53. The company has a fifty day moving average price of $161.82 and a 200 day moving average price of $155.99. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the prior year, the company earned $2.66 earnings per share. The business’s revenue was up 5.2% compared to the same quarter last year. Sell-side analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.27%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s payout ratio is currently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.